{"id":"NCT03098797","sponsor":"Stealth BioTherapeutics Inc.","briefTitle":"A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome","officialTitle":"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety and Efficacy of Subcutaneous Injections of Elamipretide in Subjects With Genetically Confirmed Barth Syndrome Followed by Open-Label Treatment","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-07-05","primaryCompletion":"2018-10-05","completion":"2021-10-11","firstPosted":"2017-04-04","resultsPosted":"2024-04-16","lastUpdate":"2024-04-16"},"enrollment":12,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Barth Syndrome"],"interventions":[{"type":"DRUG","name":"Elamipretide","otherNames":["MTP-131"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo Comparator"]}],"arms":[{"label":"Elamipretide, then Placebo","type":"EXPERIMENTAL"},{"label":"Placebo , then Elamipretide","type":"PLACEBO_COMPARATOR"}],"summary":"A randomized, double-blind cross over trial to evaluate the safety, efficacy, and tolerability of elamipretide in subjects with Barth syndrome.","primaryOutcome":{"measure":"Part 1: Distance Walked During the 6-Minute Walk Test (6MWT) by Visit","timeFrame":"Pre-dose to Week 12 (end of treatment)","effectByArm":[{"arm":"Experimental: Elamipretide","deltaMin":400.1,"sd":55.07},{"arm":"Placebo","deltaMin":412.6,"sd":60.16}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["40281531","37180415"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":5},"commonTop":["Injection site erythema","Injection site pain","Injection site pruritus","Injection site induration","Dizziness"]}}